340 related articles for article (PubMed ID: 27591964)
1. GLP-1 as a target for therapeutic intervention.
Rajeev SP; Wilding J
Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
[TBL] [Abstract][Full Text] [Related]
2. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
3. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
Nauck M; Wilhelm B
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
[TBL] [Abstract][Full Text] [Related]
4. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
5. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
6. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Darmon P; Raccah D
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
[TBL] [Abstract][Full Text] [Related]
7. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
[TBL] [Abstract][Full Text] [Related]
8. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
9. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.
Smits MM; Ten Kulve JS; van Bloemendaal L; Tonneijck L; Muskiet MHA; Kramer MHH; Ijzerman RG; van Raalte DH
Nutrition; 2019; 67-68():110524. PubMed ID: 31415908
[TBL] [Abstract][Full Text] [Related]
11. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
12. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
[TBL] [Abstract][Full Text] [Related]
13. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
[No Abstract] [Full Text] [Related]
16. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
17. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
Manigault KR; Thurston MM
Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]